19 / 42
Tumor response rate by PDL1 expression only
n/N (%)
95% CI
High PD-L1
expression*
(n=154)
Low PD-L1
expression*
(n=116)
Total
(n=287)
†
RECIST response (ORR)
‡
39/154 (25.3%)
18.7–33.0
7/115 (6.1%)
2.5–12.1
50/285 (17.5%)
13.3–22.5
Treatment setting
First line
14/49 (28.6%)
16.6–43.3
1/9 (11.1%)
0.3–48.2
16/59 (27.1%)
16.4–40.3
Second line
12/46 (26.1%)
14.3–41.1
1/24 (4.2%)
0.1–21.1
15/80 (18.8%)
10.9–29.0
≥Third line
13/59 (22.0%)
12.3–34.7
5/82 (6.1%)
2.0–13.7
19/146 (13.0%)
8.0–19.6
Pembrolizumab
RR 45% in PDL1
expression >50%
Antonia et al ASCO 2017